{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-048736","form_type":"8-K","ticker":"BMRN","cik":"0001048477","company_name":"BIOMARIN PHARMACEUTICAL INC","filed_at":"2026-02-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.462237+00:00","generated_at":"2026-05-16T02:54:26.521368+00:00","sec_items":["1.01","2.03","7.01","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BioMarin closes $850M 5.500% senior notes offering to fund Amicus acquisition","bullets":["Closed private placement of $850M 5.500% senior notes due 2034 at 100% issue price.","Net proceeds, combined with $2B term loan B, $800M term loan A, and cash, to fund Amicus acquisition.","Notes held in escrow; if acquisition not completed by Dec 19, 2026, notes redeemed at par plus accrued interest.","Notes guaranteed by certain subsidiaries; after closing, Amicus and its subsidiaries will also guarantee.","Expects to enter $600M senior secured revolving credit facility in connection with the acquisition."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-048736","json":"https://secwatch.observer/filing/0001193125-26-048736.json","markdown":"https://secwatch.observer/filing/0001193125-26-048736.md","text":"https://secwatch.observer/filing/0001193125-26-048736.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1048477/000119312526048736/0001193125-26-048736-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1048477/000119312526048736/d63881d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T02:54:26.521368+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e526acfdacb0ec7c2b07659766d8649165c432c4","claim":"BIOMARIN PHARMACEUTICAL INC incurred senior notes of $850 million aggregate principal amount at 5.500% maturing 2026.","evidence_excerpt":"On February 12, 2026, BioMarin Pharmaceutical Inc. (BioMarin or the company) completed its previously-announced private placement of $850 million aggregate principal amount of 5.500% Senior Notes due 2026 (the Notes) to several investment banks acting as initial purchasers who subsequently resold the Notes to qualified institutional buyers as defined in Rule 144A under the Securities Act of 1933, as amended (the Securities Act) and outside the United States to non-U.S. persons pursuant to Regulation S under the Securities Act.","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1048477/000119312526048736/0001193125-26-048736-index.htm","confidence":0.9},{"claim_id":"d506b5482c34cd5cf1875e2b22420902cb689f05","claim":"BIOMARIN PHARMACEUTICAL INC entered into Indenture with U.S. Bank Trust Company, National Association, as trustee valued at $850 million aggregate principal amount (effective 2026-02-12).","evidence_excerpt":"On February 12, 2026, BioMarin Pharmaceutical Inc. (BioMarin or the company) completed its previously-announced private placement of $850 million aggregate principal amount of 5.500% Senior Notes due 2026 (the Notes) to several investment banks acting as initial purchasers who subsequently resold the Notes to qualified institutional buyers as defined in Rule 144A under the Securities Act of 1933, as amended (the Securities Act) and outside the United States to non-U.S. persons pursuant to Regulation S under the Securities Act.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1048477/000119312526048736/0001193125-26-048736-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001437749-26-019166","ticker":"GVA","company_name":"GRANITE CONSTRUCTION INC","filed_at":"2026-06-02T20:17:31+00:00","headline":"Granite issues $600M 6.375% notes due 2034; redeems $273.7M convertibles, expects ~$500M derivative charge","event_type":"debt","sec_items":["1.01","2.03","7.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: debt_financing, material_agreement","same SEC item: 1.01, 2.03, 7.01, 9.01","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-019166","json":"https://secwatch.observer/filing/0001437749-26-019166.json","markdown":"https://secwatch.observer/filing/0001437749-26-019166.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/861459/000143774926019166/0001437749-26-019166-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/861459/000143774926019166/gva20260601_8k.htm"},"side_by_side_evidence":{"fact_type":"debt_financing","source_excerpt":"On February 12, 2026, BioMarin Pharmaceutical Inc. (BioMarin or the company) completed its previously-announced private placement of $850 million aggregate principal amount of 5.500% Senior Notes due 2026 (the Notes) to several investment banks acting as initial purchasers who subsequently resold the Notes to qualified institutional buyers as defined in Rule 144A under the Securities Act of 1933, as amended (the Securities Act) and outside the United States to non-U.S. persons pursuant to Regulation S under the Securities Act.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1048477/000119312526048736/0001193125-26-048736-index.htm","comparable_excerpt":"On June 2, 2026, Granite Construction Incorporated (the “Company”) closed its offering of $600.0 million aggregate principal amount of its 6.375% senior notes due 2034 (the “Notes”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/861459/000143774926019166/0001437749-26-019166-index.htm"}},{"accession":"0001213900-26-054183","ticker":"EMAT","company_name":"Evolution Metals & Technologies Corp.","filed_at":"2026-05-11T23:59:59+00:00","headline":"EMAT secures $100M convertible debenture facility from Yorkville; first $20M tranche issued","event_type":"debt","sec_items":["1.01","2.03","3.02","7.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: debt_financing, material_agreement","same SEC item: 1.01, 2.03, 7.01, 9.01","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-054183","json":"https://secwatch.observer/filing/0001213900-26-054183.json","markdown":"https://secwatch.observer/filing/0001213900-26-054183.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1866226/000121390026054183/0001213900-26-054183-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1866226/000121390026054183/ea0290073-8k_evolution.htm"},"side_by_side_evidence":{"fact_type":"debt_financing","source_excerpt":"On February 12, 2026, BioMarin Pharmaceutical Inc. (BioMarin or the company) completed its previously-announced private placement of $850 million aggregate principal amount of 5.500% Senior Notes due 2026 (the Notes) to several investment banks acting as initial purchasers who subsequently resold the Notes to qualified institutional buyers as defined in Rule 144A under the Securities Act of 1933, as amended (the Securities Act) and outside the United States to non-U.S. persons pursuant to Regulation S under the Securities Act.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1048477/000119312526048736/0001193125-26-048736-index.htm","comparable_excerpt":"The first Convertible Debenture (the “First Debenture”) in the principal amount of $20,000,000 was issued on May 7, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1866226/000121390026054183/0001213900-26-054183-index.htm"}},{"accession":"0001104659-26-069463","ticker":"FLEX","company_name":"FLEX LTD.","filed_at":"2026-06-02T20:05:59+00:00","headline":"Flex Ltd. enters $1.45B senior term loan facility; proceeds to refinance acquisition debt","event_type":"debt","sec_items":["1.01","2.03","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: debt_financing, material_agreement","same SEC item: 1.01, 2.03, 9.01","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-069463","json":"https://secwatch.observer/filing/0001104659-26-069463.json","markdown":"https://secwatch.observer/filing/0001104659-26-069463.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/866374/000110465926069463/0001104659-26-069463-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/866374/000110465926069463/tm2615696d1_8k.htm"},"side_by_side_evidence":{"fact_type":"debt_financing","source_excerpt":"On February 12, 2026, BioMarin Pharmaceutical Inc. (BioMarin or the company) completed its previously-announced private placement of $850 million aggregate principal amount of 5.500% Senior Notes due 2026 (the Notes) to several investment banks acting as initial purchasers who subsequently resold the Notes to qualified institutional buyers as defined in Rule 144A under the Securities Act of 1933, as amended (the Securities Act) and outside the United States to non-U.S. persons pursuant to Regulation S under the Securities Act.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1048477/000119312526048736/0001193125-26-048736-index.htm","comparable_excerpt":"On May 29, 2026 (the “Closing Date”), Flex Ltd. (the “Company”) entered into a Credit Agreement (the “Credit Agreement”), by and among the Company, as borrower, the lenders party thereto, and Citibank, N.A., as administrative agent, which provides a senior term loan credit facility (the “Credit Facility”) in an aggregate amount of $1.45 billion.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/866374/000110465926069463/0001104659-26-069463-index.htm"}},{"accession":"0001193125-26-252668","ticker":"BTU","company_name":"PEABODY ENERGY CORP","filed_at":"2026-06-02T14:17:48+00:00","headline":"Peabody prices $250M convertible notes due 2031, repurchases $241.2M of 2028 notes","event_type":"debt","sec_items":["1.01","2.03","3.02","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: debt_financing, material_agreement","same SEC item: 1.01, 2.03, 9.01","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-252668","json":"https://secwatch.observer/filing/0001193125-26-252668.json","markdown":"https://secwatch.observer/filing/0001193125-26-252668.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1064728/000119312526252668/0001193125-26-252668-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1064728/000119312526252668/d112966d8k.htm"},"side_by_side_evidence":{"fact_type":"debt_financing","source_excerpt":"On February 12, 2026, BioMarin Pharmaceutical Inc. (BioMarin or the company) completed its previously-announced private placement of $850 million aggregate principal amount of 5.500% Senior Notes due 2026 (the Notes) to several investment banks acting as initial purchasers who subsequently resold the Notes to qualified institutional buyers as defined in Rule 144A under the Securities Act of 1933, as amended (the Securities Act) and outside the United States to non-U.S. persons pursuant to Regulation S under the Securities Act.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1048477/000119312526048736/0001193125-26-048736-index.htm","comparable_excerpt":"additional $25 million in aggregate principal amount of the Notes (together with the “Initial Notes,” the “Notes”), bringing the total aggregate principal amount of the Notes to $250 million. On June 2, 2026, the Company completed the private offering of the Notes. The Notes are senior unsecured obligations of the Company. The net proceeds from this offering were","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1064728/000119312526252668/0001193125-26-252668-index.htm"}},{"accession":"0001882781-26-000041","ticker":"CBLO","company_name":"C2 Blockchain, Inc.","filed_at":"2026-06-02T14:08:44+00:00","headline":"C2 Blockchain raises $130K and up to $1.2M via convertible notes with heavy dilution","event_type":"debt","sec_items":["1.01","2.03","3.02","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: debt_financing, material_agreement","same SEC item: 1.01, 2.03, 9.01","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001882781-26-000041","json":"https://secwatch.observer/filing/0001882781-26-000041.json","markdown":"https://secwatch.observer/filing/0001882781-26-000041.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1882781/000188278126000041/0001882781-26-000041-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1882781/000188278126000041/form8k6226o.htm"},"side_by_side_evidence":{"fact_type":"debt_financing","source_excerpt":"On February 12, 2026, BioMarin Pharmaceutical Inc. (BioMarin or the company) completed its previously-announced private placement of $850 million aggregate principal amount of 5.500% Senior Notes due 2026 (the Notes) to several investment banks acting as initial purchasers who subsequently resold the Notes to qualified institutional buyers as defined in Rule 144A under the Securities Act of 1933, as amended (the Securities Act) and outside the United States to non-U.S. persons pursuant to Regulation S under the Securities Act.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1048477/000119312526048736/0001193125-26-048736-index.htm","comparable_excerpt":"On May 22, 2026, the Company entered into a Securities Purchase Agreement with Auctus Fund, LLC (“Auctus”), pursuant to which the Company issued and sold a Promissory Note in the principal amount of $130,000 (the “Auctus Note”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1882781/000188278126000041/0001882781-26-000041-index.htm"}},{"accession":"0001628280-26-039479","ticker":"VVX","company_name":"V2X, Inc.","filed_at":"2026-06-01T20:10:20+00:00","headline":"V2X refinances $868.5M term loans with new tranche maturing 2030; SOFR+2% margin","event_type":"debt","sec_items":["1.01","2.03","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: debt_financing, material_agreement","same SEC item: 1.01, 2.03, 9.01","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-039479","json":"https://secwatch.observer/filing/0001628280-26-039479.json","markdown":"https://secwatch.observer/filing/0001628280-26-039479.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1601548/000162828026039479/0001628280-26-039479-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1601548/000162828026039479/vec-20260529.htm"},"side_by_side_evidence":{"fact_type":"debt_financing","source_excerpt":"On February 12, 2026, BioMarin Pharmaceutical Inc. (BioMarin or the company) completed its previously-announced private placement of $850 million aggregate principal amount of 5.500% Senior Notes due 2026 (the Notes) to several investment banks acting as initial purchasers who subsequently resold the Notes to qualified institutional buyers as defined in Rule 144A under the Securities Act of 1933, as amended (the Securities Act) and outside the United States to non-U.S. persons pursuant to Regulation S under the Securities Act.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1048477/000119312526048736/0001193125-26-048736-index.htm","comparable_excerpt":"The Amendment provides for, among other things, a new tranche of term loans under the Credit Agreement in an aggregate original principal amount of $868,522,978.38 (the “New Term Loans”), which New Term Loans replace or refinance in full all of the existing term loans outstanding under the Credit Agreement (as in effect immediately prior to the Amendment), as further set forth in the Amendment. The New Term Loans mature on December 6, 2030.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1601548/000162828026039479/0001628280-26-039479-index.htm"}},{"accession":"0001805833-26-000030","ticker":"SST","company_name":"System1, Inc.","filed_at":"2026-06-01T13:00:19+00:00","headline":"System1 exchanges $302.6M debt for $150M term loan, $39.3M preferred stock, and cash","event_type":"debt","sec_items":["1.01","2.03","3.02","7.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same fact type: debt_financing","same SEC item: 1.01, 2.03, 7.01, 9.01","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001805833-26-000030","json":"https://secwatch.observer/filing/0001805833-26-000030.json","markdown":"https://secwatch.observer/filing/0001805833-26-000030.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1805833/000180583326000030/0001805833-26-000030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1805833/000180583326000030/sst-20260529.htm"},"side_by_side_evidence":{"fact_type":"debt_financing","source_excerpt":"On February 12, 2026, BioMarin Pharmaceutical Inc. (BioMarin or the company) completed its previously-announced private placement of $850 million aggregate principal amount of 5.500% Senior Notes due 2026 (the Notes) to several investment banks acting as initial purchasers who subsequently resold the Notes to qualified institutional buyers as defined in Rule 144A under the Securities Act of 1933, as amended (the Securities Act) and outside the United States to non-U.S. persons pursuant to Regulation S under the Securities Act.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1048477/000119312526048736/0001193125-26-048736-index.htm","comparable_excerpt":"specified in the Exchange Agreement on the terms and subject to the conditions set forth therein. The consideration under the Exchange Agreement consists of (i) a new $150.0 million term loan facility held by the Participating Lenders (the “Priority Term Loans”), (ii) the issuance of 39,250 shares of Series A Cumulative Convertible Preferred Stock (the","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1805833/000180583326000030/0001805833-26-000030-index.htm"}},{"accession":"0001493152-26-026839","ticker":"ILAL","company_name":"International Land Alliance Inc.","filed_at":"2026-06-02T18:24:31+00:00","headline":"International Land Alliance raises up to $385K via convertible note and warrant","event_type":"debt","sec_items":["1.01","2.03","3.02"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: debt_financing, material_agreement","same SEC item: 1.01, 2.03","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-026839","json":"https://secwatch.observer/filing/0001493152-26-026839.json","markdown":"https://secwatch.observer/filing/0001493152-26-026839.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1657214/000149315226026839/0001493152-26-026839-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1657214/000149315226026839/form8-k.htm"},"side_by_side_evidence":{"fact_type":"debt_financing","source_excerpt":"On February 12, 2026, BioMarin Pharmaceutical Inc. (BioMarin or the company) completed its previously-announced private placement of $850 million aggregate principal amount of 5.500% Senior Notes due 2026 (the Notes) to several investment banks acting as initial purchasers who subsequently resold the Notes to qualified institutional buyers as defined in Rule 144A under the Securities Act of 1933, as amended (the Securities Act) and outside the United States to non-U.S. persons pursuant to Regulation S under the Securities Act.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1048477/000119312526048736/0001193125-26-048736-index.htm","comparable_excerpt":"On May 19, 2026, International Land Alliance, Inc., a Wyoming corporation (“Company”) entered into a Securities Purchase Agreement transaction with an accredited investor (“Investor”) pursuant to which the Company issued to Investor a convertible promissory note in the aggregate principal amount up to $385,000 (“Note”)","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1657214/000149315226026839/0001493152-26-026839-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}